证券代码：300453 证券简称：三鑫医疗 公告编号：2025-034 江西三鑫医疗科技股份有限公司 关于对外投资在香港设立全资子公司的公告 （一）投资目的及对公司的影响 本次对外投资在香港设立全资子公司是公司实施发展战略的重要举措，有利 于加强公司与国际市场的合作交流和海外业务的拓展，对公司长期发展和战略布 局具有积极影响，符合公司的发展战略。公司本次对外投资拟以自有资金出资， 不会对公司财务及经营情况产生重大影响，也不存在损害公司及股东利益的情形。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、对外投资概述 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 1 日 召开了第五届董事会第二十次会议，审议通过了《关于对外投资在香港设立全资 子公司的议案》，同意公司以自有资金投资 10 万美元在中国香港设立全资子公 司三鑫医疗（香港）有限公司（最终名称以登记注册结果为准，以下简称"香港 三鑫"）。香港三鑫注册资本为 10 万美元，公司持有其 100%股权。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-033 江西三鑫医疗科技股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 江西三鑫医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十 次会议通知于 2025 年 6 月 27 日以电子邮件方式发出，并于 2025 年 7 月 1 日上 午 9:00 在公司会议室召开。本次会议采用现场及通讯的方式进行，会议应参加 表决董事 8 名，实际参加表决董事 8 名，其中：董事乐珍荣先生，独立董事陈国 锋先生、夏晓华先生、蒋海洪先生以通讯方式参加了本次会议并进行表决。会议 由董事长彭义兴先生召集并主持，公司监事和高级管理人员列席了本次会议。本 次会议的内容以及召集、召开的方式、程序均符合《中华人民共和国公司法》《公 司章程》的有关规定，合法有效。 二、董事会会议审议情况 特此公告。 江西三鑫医疗科技股份有限公司董事会 本次会议审议通过了以下议案： （一）审议通过《关于对外投资在香港设立全资子公司的议案》 为加强公司与国际市场的合作交流并拓 ...

医疗器械注册证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）控股子公司成都威力 生生物科技有限公司（以下简称"成都威力生"）于近日获得了由四川省药品监 督管理局颁发的《医疗器械注册证》，现将主要情况公告如下： 二、对公司的影响 证券代码：300453 证券简称：三鑫医疗 公告编号：2025-032 江西三鑫医疗科技股份有限公司 关于控股子公司获得移动式血液透析用制水系统 江西三鑫医疗科技股份有限公司董事会 2025 年 6 月 18 日 成都威力生是专业从事血液净化系列医疗设备研发、制造和销售的国家高新 技术企业，能为医院和透析中心提供包括血液透析机、血液透析滤过机、血液透 析制水系统及血液透析集中供液系统在内的整体解决方案。 影响。 该产品的实际销售情况取决于未来市场推广效果，公司目前尚无法预测其对 公司未来业绩的具体影响，敬请广大投资者予以关注并注意投资风险。 特此公告。 成都威力生本次获得医疗器械注册证的移动式血液透析用制水系统由颗粒 过滤器、活性炭过滤器（滤芯式过滤器）、软化器（滤芯式过滤器）、反渗透 ...

Core Viewpoint - Sanxin Medical (300453) announced that its subsidiary Chengdu Weili Sheng Biotechnology Co., Ltd. has obtained a Medical Device Registration Certificate from the Sichuan Provincial Drug Administration, which is valid from June 17, 2025, to June 16, 2030 [1] Summary by Category - **Company Development** - Chengdu Weili Sheng Biotechnology Co., Ltd. received the Medical Device Registration Certificate with the number Chuan Xie Zhu Zheng 20252100086 [1] - The certificate is applicable for the preparation of water for hemodialysis, powder preparation for concentrated liquid, dialysis solution preparation, and reuse of dialyzers [1] - **Regulatory Approval** - The Medical Device Registration Certificate is issued by the Sichuan Provincial Drug Administration, indicating compliance with local regulatory standards [1] - The validity period of the certificate spans five years, enhancing the company's operational capabilities in the medical device sector [1]

Company Overview - Jiangxi Sanxin Medical Technology Co., Ltd. specializes in the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical instruments [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] - The company has been recognized as a "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration of China [2] Financial Performance - In the first quarter of 2025, the company reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The gross profit margin for the same period was 34.62% [2] Market Position - As of May 28, the company's stock closed at 8.19 yuan, up 4.20%, with a rolling price-to-earnings (PE) ratio of 18.81, marking a new low in 46 days [1] - The average PE ratio for the medical device industry is 48.81, with a median of 35.46, placing Sanxin Medical at the 44th position in the industry ranking [1][3] - The total market capitalization of the company is 4.278 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,367, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-031 江西三鑫医疗科技股份有限公司 特此公告。 江西三鑫医疗科技股份有限公司董事会 关于获得预充式导管冲洗器医疗器械注册证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于近日获得了由国家 药品监督管理局颁发的《医疗器械注册证》，现将主要情况公告如下： 二、对公司的影响 公司本次获得医疗器械注册证的预充式导管冲洗器由外套、活塞、芯杆、锥 头、护帽及 0.9%氯化钠注射液组成。预充式导管冲洗器为一次性使用无菌产品， 采用无针设计、预充式设计和防回血设计，提升医护人员操作的安全性和便利性， 同时降低患者的感染风险。 公司取得"预充式导管冲洗器"产品注册证，进一步延伸了公司给药器具类 产品线，将为临床治疗提供更加安全、高效的导管护理解决方案，对公司未来生 产经营将产生积极影响。 该产品的实际销售情况取决于未来市场推广效果，公司目前尚无法预测其对 公司未来业绩的具体影响，敬请广大投资者予以关注并注意投资风险。 2025 年 5 月 29 日 序号 产品名 ...

Core Viewpoint - Sanxin Medical (300453) has recently obtained a Medical Device Registration Certificate from the National Medical Products Administration for its pre-filled catheter flushing device, which is expected to enhance safety and efficiency in clinical treatments [1] Product Registration Details - The product is classified as Class III and is designed for the closure and flushing of catheter ends during various drug treatments [1] - The registration certificate number is 20253140981, valid from May 27, 2025, to May 26, 2030 [1] Product Features - The device is a single-use sterile product featuring a needle-free design, pre-filled design, and anti-reflux design, which improves operational safety for healthcare personnel and reduces infection risks for patients [1] Business Impact - The acquisition of this registration certificate extends the company's product line in drug delivery devices, providing safer and more efficient catheter care solutions, which is expected to have a positive impact on the company's future production and operations [1]

Group 1: Sales and Market Expansion - The company is currently experiencing normal production and operational conditions, with key financial data to be disclosed in the 2025 semi-annual report [2] - The company aims to selectively participate in domestic and international blood purification exhibitions and academic conferences based on market development plans [2] - The ASEAN market is identified as a key overseas target market, with sales already achieved in most ASEAN countries, particularly in Indonesia, Malaysia, Thailand, and Vietnam [3] Group 2: International Market Development - The company is accelerating the certification process for its blood purification products in Russia and Turkey, following successful registrations in countries like Indonesia, Peru, and Mexico [3] - The company has established a global self-certification system to enhance its international market layout and competitiveness [3] Group 3: Financial Performance and Shareholder Relations - The company has maintained a high dividend payout ratio and is focused on improving investor relations and information disclosure quality [3] - Future plans for share buybacks or increases in shareholding will be disclosed in accordance with legal regulations [3] Group 4: Product Development and Innovation - The company has not yet ventured into AI medical technology but is monitoring developments in this area for potential future applications [3] - The company is committed to innovation in blood purification products and exploring other treatment models to meet healthcare demands [5] Group 5: Manufacturing and Strategic Expansion - The company has established multiple manufacturing bases across China, enhancing its industry position and core competitiveness [4] - Future expansion into first-tier cities will be considered based on strategic needs [4]

Core Insights - The company is a key player in the blood dialysis equipment industry, having established a complete product chain through independent research and development, and has provided over 300 million dialysis services to more than 5,000 hospitals and dialysis centers domestically and internationally [1] - The company anticipates a sales revenue growth of over 100% for blood dialysis equipment in 2024, indicating an increase in market share and enhanced competitiveness within the industry [1] - The company is actively pursuing digital transformation and the construction of smart factories, which are expected to improve operational efficiency and management effectiveness [1] Industry Positioning - The company has expanded its footprint by investing in or acquiring subsidiaries across various regions, achieving a comprehensive layout of the blood dialysis product supply chain and enhancing its industry position and core competitiveness [2] - The company views overseas markets as a significant growth opportunity, with successful registrations in countries like Indonesia, Peru, and Mexico, and is accelerating certification processes in Russia and Turkey [2] - The ASEAN market is identified as one of the most promising growth areas for blood dialysis, with the company already achieving sales in most ASEAN countries, particularly in Indonesia, Malaysia, Thailand, and Vietnam [2]

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-030 江西三鑫医疗科技股份有限公司 关于完成工商变更登记暨《公司章程》备案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、基本情况 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2024 年 10 月 14 日召开第五届董事会第十六次会议，审议通过了《关于增加注册资本并修订<公 司章程>的议案》，同意公司根据 2021 年第一次临时股东大会审议通过的《关于 提请公司股东大会授权董事会办理股权激励相关事宜的议案》和 2021 年限制性 股票激励计划第三个归属期归属事项，变更注册资本并修订《公司章程》，具体 内容详见公司于 2024 年 10 月 15 日在巨潮资讯网披露的《关于增加注册资本并 修订<公司章程>的公告》（公告编号：2024-092）。 公司于 2025 年 3 月 25 日和 2025 年 4 月 25 日分别召开第五届董事会第十八 次会议、2024 年年度股东大会，审议通过了《关于修订<公司章程>的议案》， 同意公司对《公司章程》的部分条款进行修订。具体内容详见公司于 ...